Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Poland

- PMLiVE

GSK’s RSV vaccine approved by European Commission for older adults

RSV infections in older adults account for over 170,000 hospitalisations each year in Europe

- PMLiVE

GSK’s five-in-one meningococcal vaccine candidate shows promise in phase 3 trial

There are no approved vaccines offering simultaneous protection against all five serogroups

- PMLiVE

GSK welcomes Canadian court ruling to dismiss Zantac litigation

The company and other drugmakers have been facing thousands of lawsuits claiming ranitidine caused cancer

- PMLiVE

GSK’s RSV vaccine approved by FDA for older adults

Arexvy is the first RSV vaccine for this age group to be approved anywhere in the world

- PMLiVE

CureVac announces start of phase 1/2 seasonal influenza vaccine trial

The multivalent mRNA candidates have been developed in collaboration with GSK

- PMLiVE

GSK’s RSV vaccine candidate recommended by CHMP for older adults

RSV infections in older adults account for over 270,000 hospitalisations each year in Europe

- PMLiVE

GSK to acquire Bellus Health for approximately $2bn

The deal includes the biotech’s late-stage candidate for refractory chronic cough

- PMLiVE

GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate

There are currently no licensed vaccines offering simultaneous protection against all five serogroups

- PMLiVE

Results for GSK’s RSV vaccine candidate published in New England Journal of Medicine

RSV infections in older adults account for around 6,000 to 10,000 deaths in the US each year

- PMLiVE

GSK and Vir Biotech amend COVID-19 research partnership

Vir will now advance new antibodies and vaccines for COVID-19 alone or with other partners

- PMLiVE

GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis

The rare autoimmune disease affects two to ten people per million and has limited treatments

- PMLiVE

GSK and CureVac to advance mRNA COVID-19 and flu vaccine candidates

The vaccines produced promising preliminary results in phase 1 trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links